First Postpartum Depression Drug Fast Tracked and Licensed by FDA
On Aug. 4, 2023, the U.S. Food and Drug Administration (FDA) fast tracked licensure of the oral prescription medication Zurzuvae (zuranolone), manufactured by Sage Therapeutics, Inc. as a treatment for postpartum depression. Postpartum affects roughly one in seven women and typically begins after childbirth but, for some women, it can begin during later stages of […]
Chemical Imbalance Not a Major Cause of Depression, Studies Find
A new study published recently in the Journal of Molecular Psychiatry questions the hypothesis that serotonin inhibition is the cause of most depression disorders. About 21 million Americans are affected by major depressive disorder with one in six Americans taking antidepressant medication.1 2 3 The serotonin theory of depression came about in the 1950’s when […]
Anti-Depressants in Short Supply During COVID-19 Lockdowns
Drug shortages listed by the U.S Food and Drug Administration (FDA) are exposing some of the ramifications of responses to the COVID-19 pandemic, including state lockdowns and social distancing regulations.1 Zoloft (sertraline hydrochloride), an anti-depressant manufactured by Pfizer and its generic counterparts produced by other drug makers, have been added to the FDA’s list of […]
